CareDx down after jury awards peer Natera $96 mln in patent trial

CareDx

29/01/2024 13:12

** Medical test maker CareDx's  CDNA.O  shares fall 10.2% to
$8.1 premarket
    ** Genetic-testing company Natera  NTRA.O  convinced a jury
in Delaware federal court late on Friday that CDNA's
kidney-transplant tests infringe one of its patents, NTRA's
spokesperson says
    ** Separately, NTRA said on Monday jury has awarded $83.7
mln in lost profits and $12.6 mln in past royalties to the co 
    ** NTRA has accused CDNA of infringing patents related to
the use of cell-free DNA to assess the risk that a person's body
will reject a kidney transplant
    ** Up to Friday's close, stock had fallen ~38% in the last
12 months 

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))